top of page

Sep 14

In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor

CEO Hervé Hoppenot describes the strategy for Incyte's PD1, and developing the CDK2 for ovarian and endometrial cancers, and possibly beyond.

Recent Posts

London Healthcare Week: The CEO of Arbutus summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting

London Healthcare Week: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections

Seoul based ABL Bio is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh

bottom of page